Skip to main content
SpringerLink
Log in

Role of E2F1 in Pancreatic Cancer

  • Chapter
  • First Online:
Role of Transcription Factors in Gastrointestinal Malignancies

  • 505 Accesses

Abstract

Pancreatic cancer is the deadliest of human cancers to date. The hostile nature of pancreatic cancer, mostly due to its tendency for early local and distant spread, is in due course responsible for poor diagnosis and reduced survival. Most of the pancreatic cancers are originated in exocrine glands. About 95% of these exocrine cancers are adenocarcinomas that affect the pancreatic ducts. Other types of pancreatic cancers include neuroendocrine cancers that arise in endocrine cells. But these provide extensive capillary networks for metastasis of tumor cells. Several computational approaches are employed to couple the gene expression measurements with a network of known relationships between gene products, like the NetRank algorithm similar to Google’s PageRank algorithm, to determine the marker genes that are better involved in clinical outcome prediction. One such marker genes are those that encode transcription factors. One important group is E2F transcription factor family. These regulate a varied range of cellular functions, which include cell differentiation, cell proliferation, and cell death. The current chapter focuses on the E2F1 transcription factor, its mechanism of regulating the cell cycle, and its role in apoptosis and metastasis in context with the devastating pancreatic cancer. The insights into the molecular mechanisms with further investigation and research may provide improved diagnostic and treatment options for this type of cancer.

The original version of this chapter was revised. The book was inadvertently published without Abstracts and Keywords, which are now included in all the chapters. An erratum to this chapter can be found at https://doi.org/10.1007/978-981-10-6728-0_39

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Global cancer statistics, www.cdc.gov/cancer/international/statistics.htm

    Google Scholar 

  2. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–1617

    Article  CAS  PubMed  Google Scholar 

  3. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK, Perrault J, Whitcomb DC (1997) Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 89(6):442–446

    Article  CAS  PubMed  Google Scholar 

  4. Kovesdi I, Reichel R, Nevins JR (1986) Identification of a cellular transcription factor involved in E1A trans-activation. Cell 45(2):219–228

    Article  CAS  PubMed  Google Scholar 

  5. Attwooll C, Denchi EL, Helin K (2004) The E2F family: specific functions and overlapping interests. EMBO J 23(24):4709–4716

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Trimarchi JM, Lees JA (2002) Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3(1):11–20

    Article  CAS  PubMed  Google Scholar 

  7. Chen R, Dawson DW, Pan S, Ottenhof NA, De Wilde RF, Wolfgang CL, ..., Waghray M (2015) Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Lab Invest 95(1):43–55

    Article  CAS  PubMed  Google Scholar 

  8. Magae J, Wu CL, Illenye S, Harlow E, Heintz NH (1996) Nuclear localization of DP and E2F transcription factors by heterodimeric partners and retinoblastoma protein family members. J Cell Sci 109(7):1717–1726

    PubMed  CAS  Google Scholar 

  9. Gaubatz S, Lees JA, Lindeman GJ, Livingston DM (2001) E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol Cell Biol 21(4):1384–1392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, ..., Nevins JR (2000) Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol 20(10):3626–3632

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Di Stefano L, Jensen MR, Helin K (2003) E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. EMBO J 22(23):6289–6298

    Article  PubMed  PubMed Central  Google Scholar 

  12. Huang B, Deo D, Xia M, Vassilev LT (2009) Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 7(9):1497–1509

    Article  CAS  PubMed  Google Scholar 

  13. Lodygin D, Menssen A, Hermeking H (2002) Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest 110(11):1717–1727

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Khanna A, Pimanda JE, Westermarck J (2013) Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 73(22):6548–6553

    Article  CAS  PubMed  Google Scholar 

  15. Korotayev K, Chaussepied M, Ginsberg D (2008a) ERK activation is regulated by E2F1 and is essential for E2F1-induced S phase entry. Cell Signal 20(6):1221–1226

    Article  CAS  PubMed  Google Scholar 

  16. Caldas C, Kern SE (1995) K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 18(1):1–6

    PubMed  CAS  Google Scholar 

  17. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant cK-ras genes. Cell 53(4):549–554

    Article  CAS  Google Scholar 

  18. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, ..., Bartram CR (1989) High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43(6):1037–1041

    Article  PubMed  Google Scholar 

  19. Fang Z et al (2015) E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Biochem Biophys Res Commun 464(2):407–415

    Article  CAS  PubMed  Google Scholar 

  20. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10(7):2307–2318

    Article  CAS  PubMed  Google Scholar 

  21. Putzer BM, Stiewe T, Crespo F, Esche H (2000) Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy. Gene Ther 7(15):1317–1325

    Article  CAS  PubMed  Google Scholar 

  22. Phillips AC, Vousden KH (2001) E2F-1 induced apoptosis. Apoptosis 6(3):173–182

    Article  CAS  PubMed  Google Scholar 

  23. Qin XQ, Livingston DM, Kaelin WG, Adams PD (1994) Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci 91(23):10918–10922

    Article  CAS  PubMed  Google Scholar 

  24. Wu X, Levine AJ (1994) p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci 91(9):3602–3606

    Article  CAS  PubMed  Google Scholar 

  25. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG (1998) Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci 95(15):8858–8863

    Article  CAS  PubMed  Google Scholar 

  26. Holmberg C, Helin K, Sehested M, KarlstroÈm O (1998) E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 17(2):143–155

    Article  CAS  PubMed  Google Scholar 

  27. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH (1997) Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 11(14):1853–1863

    Article  CAS  PubMed  Google Scholar 

  28. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, ..., Kaelin Jr WG (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407(6804):645–648

    Article  CAS  Google Scholar 

  29. Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH (1999) E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 4(5):771–781

    Article  CAS  PubMed  Google Scholar 

  30. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, ..., Kanakura Y (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9(5):1017–1029

    Article  CAS  PubMed  Google Scholar 

  31. Yamazaki K, Yajima T, Nagao T, Shinkawa H, Kondo F, Hanami K, ..., Ishida Y (2003) Expression of transcription factor E2F-1 in pancreatic ductal carcinoma: an immunohistochemical study. Pathol-Res Pract 199(1):23–28

    Article  Google Scholar 

  32. Plath T, Peters M, Detjen K, Welzel M, Von Marschall Z, Radke C, ..., Rosewicz S (2002) Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst 94(2):129–142

    Article  CAS  PubMed  Google Scholar 

  33. Elliott MJ, Farmer MR, Atienza Jr C, Stilwell A, Dong YB, Yang HL, ..., McMasters KM (2002a) E2F-1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells. Tumor Biol 23(2):76–86

    Article  CAS  PubMed  Google Scholar 

  34. Rödicker F, Stiewe T, Zimmermann S, Pützer BM (2001) Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. Cancer Res 61(19):7052–7055

    PubMed  Google Scholar 

  35. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW (1997) E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol 17(3):1049–1056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Pruschy M, Wirbelauer C, Glanzmann C, Bodis S, Krek W (1999) E2F-1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53. Cell Growth Differ 10:141–146

    PubMed  CAS  Google Scholar 

  37. Hunt KK, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, Clayman G, Hung MC (1997) Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 57(21):4722–4726

    PubMed  CAS  Google Scholar 

  38. Shan B, Lee WH (1994) Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 14(12):8166–8173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Dong YB, Yang HL, Elliott MJ, Liu TJ, Stilwell A, Atienza C, McMasters KM (1999) Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 86(10):2021–2033

    Article  CAS  PubMed  Google Scholar 

  40. Yang HL, Dong YB, Elliott MJ, Liu TJ, Atienza C, Stilwell A, McMasters KM (1999) Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin Cancer Res 5(8):2242–2250

    PubMed  CAS  Google Scholar 

  41. Liu TJ, Wang M, Breau RL, Henderson Y, El-Naggar AK, Steck KD, ..., Clayman GL (1999) Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. Cancer Gene Ther 6(2):163–172

    Article  CAS  PubMed  Google Scholar 

  42. Fueyo J, Gomez-Manzano C, Yung WKA, Liu TJ, Alemany R, McDonnell TJ, ..., Kyritsis AP (1998a) Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4(6):685–690

    Article  CAS  PubMed  Google Scholar 

  43. Stubbs MC, Strachan GD, Hall DJ (1999) An early S phase checkpoint is regulated by the E2F1 transcription factor. Biochem Biophys Res Commun 258(1):77–80

    Article  CAS  PubMed  Google Scholar 

  44. Krek W, Xu G, Livingston DM (1995) Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 83(7):1149–1158

    Article  CAS  PubMed  Google Scholar 

  45. Bilodeau JF, Faure R, Piedboeuf B, Mirault ME (2000) Hyperoxia induces S-phase cell-cycle arrest and p21 Cip1/Waf1-independent Cdk2 inhibition in human carcinoma T47D-H3 cells. Exp Cell Res 256(2):347–357

    Article  CAS  PubMed  Google Scholar 

  46. Meng RD, Phillips PETER, El-Deiry WS (1999) p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol 14(1):5–14

    PubMed  CAS  Google Scholar 

  47. Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kato T, Yuan ZM (1997) Role for E2F in DNA damage-induced entry of cells into S phase. Cancer Res 57(17):3640–3643

    PubMed  CAS  Google Scholar 

  48. Hu QL, Jiang QY, Jin X, Shen J, Wang K, Li YB, ..., Li ZH (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34(9):2265–2276

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Virology, Pune, India

    Prudhvi Lal Bhukya & Shakuntala Mahilkar

  2. Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth, Pune, India

    Divya Aravind Tiraki

Authors
  1. Prudhvi Lal Bhukya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Divya Aravind Tiraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shakuntala Mahilkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shakuntala Mahilkar .

Editor information

Editors and Affiliations

  1. Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA

    Ganji Purnachandra Nagaraju

  2. Department of Biotechnology, Krishna University, Machilipatnam, Andhra Pradesh, India

    Pallaval Veera Bramhachari

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bhukya, P.L., Tiraki, D.A., Mahilkar, S. (2017). Role of E2F1 in Pancreatic Cancer. In: Nagaraju, G., Bramhachari, P. (eds) Role of Transcription Factors in Gastrointestinal Malignancies. Springer, Singapore. https://doi.org/10.1007/978-981-10-6728-0_28

Download citation

Publish with us

Policies and ethics

Search

Navigation